Findings From the RELEVANCE Trial in Follicular Lymphoma
November 28th 2018Andre Goy, MD, chairman and director, chief of lymphoma, and director of clinical and translational cancer research at John Theurer Cancer Center, discusses data from the RELEVANCE trial, which randomized patients with follicular lymphoma in need of therapy to receive either rituximab plus lenalidomide or a physician’s choice of bendamustine and rituximab plus CHOP or R-CHOP.
Watch
Safety Data From the Phase II JULIET Trial in DLBCL
November 28th 2018Peter Borchmann, MD, discusses the safety signals seen so far in the phase II JULIET trial investigating tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment option for patients with diffuse large B-cell lymphoma.
Watch
Selecting I-O Agents and Combinations for Patients With RCC
November 27th 2018Robert A. Figlin, MD director, division of hematology/oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the considerations behind selecting an immune-oncology agent for the treatment of patients with renal cell carcinoma.
Watch